Si-Bone Inc (SIBN)

Currency in USD
14.84
+0.08(+0.54%)
Closed·
14.22-0.62(-4.18%)
·
SIBN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.5215.05
52 wk Range
11.4821.89
Key Statistics
Prev. Close
14.76
Open
14.67
Day's Range
14.52-15.05
52 wk Range
11.48-21.89
Volume
582.4K
Average Volume (3m)
733K
1-Year Change
-24.7083%
Book Value / Share
4.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SIBN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.13
Upside
+62.57%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Si-Bone Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.13
(+62.57% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy18.00+21.29%22.00MaintainMay 12, 2026
Truist Securities
Buy18.00+21.29%20.00MaintainMay 12, 2026
Truist Securities
Buy20.00+34.77%24.00MaintainApr 15, 2026
Piper Sandler
Buy25.00+68.46%-MaintainMar 23, 2026
Truist Securities
Buy24.00+61.73%23.00MaintainFeb 24, 2026

Si-Bone Inc SWOT Analysis


Surgical Innovation
SI-BONE's iFuse Implant System drives 22.6% YoY growth, establishing the company as a pioneer in minimally invasive sacroiliac joint surgery
Financial Health
Strong Q1 2025 performance with $47.3M in sales, 25% YoY increase. Healthy 79.25% gross margin and solid cash position, despite current overvaluation
Growth Trajectory
Analysts project 15-20%+ annual revenue growth. New product launches and FDA Breakthrough Device Designations poised to expand addressable market
Market Dynamics
Average analyst price target of $28.50. NTAP reimbursement of $3,960 for iFuse TORQ TNT expected in Q4 2025, potentially catalyzing adoption
Read full SWOT analysis

Si-Bone Inc Earnings Call Summary for Q1/2026

  • Si-Bone reported Q1 2026 EPS of -$0.10, beating forecast of -$0.19 by 47%; revenue rose 11.2% YoY to $52.6M, slightly missing estimates.
  • International revenue surged 33.9% while U.S. grew 10%; gross margin held steady at 79.8% with adjusted EBITDA improving 440% to $2.5M.
  • Stock rose 1.79% aftermarket to $12.49 despite trading near 52-week low; analysts maintain bullish outlook with price targets of $20-$32.
  • Company raised full-year guidance, projecting accelerated revenue growth; strong balance sheet with cash exceeding debt and 8.55 current ratio.
  • CEO Dunn emphasized successful execution of growth strategy; key risks include supply chain disruptions, competition, and regulatory changes.
Last Updated: 2026-05-11, 05:48 p/m
Read Full Transcript

Earnings

Latest Release
May 11, 2026
EPS / Forecast
-0.10 / -0.19
Revenue / Forecast
52.6M / 52.85M
EPS Revisions
Last 90 days

SIBN Income Statement

Compare SIBN to Peers and Sector

Metrics to compare
SIBN
Peers
Sector
Relationship
P/E Ratio
−39.4x−7.4x−0.5x
PEG Ratio
−1.00−0.610.00
Price/Book
3.7x4.1x2.6x
Price / LTM Sales
3.2x1.7x3.1x
Upside (Analyst Target)
61.7%38.8%55.1%
Fair Value Upside
Unlock15.3%7.2%Unlock

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
18.63M42.01%275.00M
Other Institutional Investors
26.51M57.99%391.27M
Public Companies & Retail Investors
0.000.00%0.00
Total
45.14M100.00%666.27M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
First Light Asset Management, LLC17.97%7,971,486117,659
BlackRock, Inc.6.89%3,057,03945,122

People Also Watch

29.59
CDRE
+1.09%
10.320
ERAS
+0.49%
22.710
LYTS
-3.40%
26.60
HTFL
+3.74%
7.39
AURA
-1.07%

FAQ

What Is the Si-Bone (SIBN) Stock Price Today?

The Si-Bone stock price today is 14.84 USD.

What Stock Exchange Does Si-Bone Trade On?

Si-Bone is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Si-Bone?

The stock symbol for Si-Bone is "SIBN."

What Is the Si-Bone Market Cap?

As of today, Si-Bone market cap is 658.14M USD.

What Is Si-Bone's Earnings Per Share (TTM)?

The Si-Bone EPS (TTM) is -0.39.

When Is the Next Si-Bone Earnings Date?

Si-Bone will release its next earnings report on Aug 10, 2026.

From a Technical Analysis Perspective, Is SIBN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Si-Bone Stock Split?

Si-Bone has split 0 times.

How Many Employees Does Si-Bone Have?

Si-Bone has 376 employees.

What is the current trading status of Si-Bone (SIBN)?

As of May 20, 2026, Si-Bone (SIBN) is trading at a price of 14.84 USD, with a previous close of 14.76 USD. The stock has fluctuated within a day range of 14.52 USD to 15.05 USD, while its 52-week range spans from 11.48 USD to 21.89 USD.

What Is Si-Bone (SIBN) Price Target According to Analysts?

The average 12-month price target for Si-Bone is 24.13 USD, with a high estimate of 32 USD and a low estimate of 18 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +62.57% Upside potential.

What Is the SIBN After Hours Price?

SIBN's last after hours stock price is 14.22 USD, the stock has decreased by -0.62, or -4.18%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.